Tag:

Cannabinoid

Health

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

by Chief Editor
written by Chief Editor

MIRA Pharmaceuticals’ Breakthrough: A Fresh Era for Non-Opioid Pain Relief?

Miami, FL – March 23, 2026 – MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced promising preclinical data today regarding its lead candidate, Mira-55, potentially paving the way for a novel approach to inflammatory pain management. The findings, which demonstrate a lack of typical cannabinoid-related central nervous system (CNS) side effects, could address a critical gap in the market and offer a much-needed alternative to opioids and traditional NSAIDs.

The Challenge with Current Pain Management

For millions suffering from chronic pain, the options are often limited and fraught with drawbacks. Opioids, while effective, carry significant risks of dependence, tolerance, and overdose. Nonsteroidal anti-inflammatory drugs (NSAIDs) can lead to gastrointestinal, renal, and cardiovascular issues. This creates a substantial unmet medical need for safer, more effective pain relief solutions.

Mira-55: A Differentiated Approach

MIRA Pharmaceuticals is tackling this challenge with Mira-55, a next-generation cannabinoid analog. Unlike traditional cannabinoid therapies that often activate CB1 receptors – leading to psychoactive effects – Mira-55 is designed to modulate both CB1 and CB2 receptor activity while minimizing CNS liabilities. Preclinical studies have shown that Mira-55 reduces pain sensitivity and delivers morphine-comparable analgesic effects in inflammatory pain models without producing sedation, motor impairment, or anxiety-like behavior.

Specifically, the recent data revealed that Mira-55 did not exhibit cannabinoid-like psychogenic effects in tests evaluating hypothermia, catalepsy, and behavior in the Elevated Plus Maze (EPM) and Open Field (OF). This is a significant departure from compounds like rimonabant, a CB1 receptor antagonist, which demonstrated anxiety-like effects in the same tests.

Market Potential and Growth

The potential market for non-opioid pain treatments is substantial and growing. According to Grand View Research, the global non-opioid pain treatment market was valued at approximately $45.3 billion in 2024 and is projected to reach $70.3 billion by 2030, representing a compound annual growth rate (CAGR) of 7.7%. This growth is driven by an aging population, increasing prevalence of chronic diseases, and a growing demand for safer pain management options.

Beyond Pain: MIRA’s Broader Pipeline

Mira-55 isn’t the only promising candidate in MIRA Pharmaceuticals’ pipeline. The company is also developing Ketamir-2 for neuropathic pain and SKNY-1 targeting obesity and smoking cessation. This diversified approach positions MIRA to address multiple significant healthcare challenges.

Expert Insight: Separating Biology from Side Effects

“The challenge in cannabinoid drug development has never been the biology—it’s been separating it from CNS side effects,” stated Erez Aminov, Chairman and CEO of MIRA. “We believe Mira-55 may represent an important step in that direction as we advance toward clinical development in inflammatory pain.”

Future Trends in Cannabinoid-Based Therapeutics

MIRA’s work with Mira-55 highlights several key trends shaping the future of cannabinoid-based therapeutics:

  • Targeted Cannabinoid Analogs: The development of compounds like Mira-55, designed to selectively modulate cannabinoid receptors and minimize unwanted side effects, is likely to accelerate.
  • Focus on Non-Psychoactive Therapies: The demand for pain relief and other therapeutic benefits without the psychoactive effects associated with traditional cannabis will drive innovation in this area.
  • Expanding Applications: Beyond pain management, cannabinoid-based therapies are being explored for a wide range of conditions, including anxiety, cognitive decline, and metabolic disorders.
  • Rigorous Preclinical and Clinical Evaluation: As the field matures, more rigorous scientific evaluation will be crucial to establish the efficacy and safety of cannabinoid-based therapies.

FAQ

Q: What is Mira-55?
A: Mira-55 is a next-generation cannabinoid analog being developed by MIRA Pharmaceuticals for the treatment of inflammatory pain.

Q: What makes Mira-55 different from other cannabinoid therapies?
A: Mira-55 is designed to minimize CNS side effects commonly associated with traditional cannabinoid therapies.

Q: What is the projected market size for non-opioid pain treatments?
A: The global non-opioid pain treatment market is projected to reach $70.3 billion by 2030, growing at a CAGR of 7.7%.

Q: What other programs does MIRA Pharmaceuticals have in development?
A: MIRA Pharmaceuticals is also developing Ketamir-2 for neuropathic pain and SKNY-1 targeting obesity and smoking cessation.

Did you realize? The global pain management market is estimated to be worth over $75 billion, highlighting the significant unmet need for innovative therapies.

Pro Tip: Stay informed about clinical trial updates for Mira-55 and other promising pain management therapies through MIRA Pharmaceuticals’ website and reputable medical news sources.

Explore more articles on pharmaceutical innovation and biotechnology advancements on our website. Learn more about MIRA Pharmaceuticals.

0 comments
0 FacebookTwitterPinterestEmail
Health

Study shows long-term cannabis use disrupts critical brain processes

by Chief Editor
written by Chief Editor

The Growing Impact of Chronic Cannabis Use on Brain Function

The rising tide of cannabis legalization worldwide has led to increased use, raising concerns over its long-term effects on brain health. A recent study published in JAMA Network Open sheds light on how heavy, lifetime cannabis use can alter brain activation during cognitive tasks, particularly those involving decision-making and memory. As the global conversation continues, understanding these implications becomes crucial.

Understanding Brain Changes Through Research

Researchers from the Human Connectome Project analyzed data from 1,003 adults aged 22–36 using functional magnetic resonance imaging (fMRI) during various cognitive tasks. This included studies in working memory and motor function. By categorizing cannabis use into nonuser, moderate user, and heavy user based on self-reports, and confirming recent use with urine toxicology, a comprehensive analysis of THC’s impact on the brain was achieved.

Who’s Affected? The Nuances of Cannabis-Induced Brain Changes

The study highlighted specific brain regions like the dorsolateral prefrontal cortex (dlPFC) and dorsomedial prefrontal cortex (dmPFC), which are critical for cognitive tasks. Heavy cannabis users showed reduced brain activation in these areas, suggesting potential neural adaptations from chronic THC exposure. Surprisingly, recent use did not consistently affect brain activation when accounting for other factors, though it did dampen cognitive efficiency.

Sex-Specific Differences Reveal More

Men and women appear to experience these brain changes differently. Male participants showed reduced brain activation during motor tasks, while female participants did not exhibit similar patterns. This intriguing difference hints at underlying biological or hormonal influences that further research needs to explore.

Real-World Implications and Public Awareness

Chronic cannabis use poses risks, especially in professions requiring high cognitive function, such as driving or operating heavy machinery. Public health education is paramount to inform individuals about these risks, particularly as cannabis becomes more integrated into daily life.

Looking Ahead: Future Trends and Research

As cannabis use becomes normalized, ongoing research will be crucial to understand its long-term impacts. Longitudinal studies will help clarify whether these brain changes are reversible or permanent. Policymakers and educators must stay informed to mitigate potential risks associated with heavy cannabis use.

FAQs About Cannabis and Brain Function

  • How does cannabis affect memory? Chronic use can impair memory functions, notably affecting the brain regions responsible for working memory.
  • Are recent users at risk? While long-term users face persistent changes, recent use may temporarily decrease cognitive performance, but its lasting impact is still under investigation.
  • What should I consider before using cannabis? Consider the long-term cognitive effects and consult healthcare professionals for advice based on your health background.

Did you know? The primary psychoactive component, THC, might cause long-term changes in brain regions rich in cannabinoid receptors. This highlights the necessity for more research and awareness about chronic cannabis use.

Pro Tip: If you’re in a role requiring high-level decision-making, consider moderated cannabis use or alternative relaxation methods.

Engage with Us

What are your thoughts on the potential cognitive effects of cannabis? Have you observed any noticeable changes in decision-making or memory in yourself or others? Share your insights with us and join the conversation. For more information on cannabis and health, visit Healthline, or explore our related articles for deeper insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Study identifies potential pathway to improve memory in neurodegenerative diseases

by Chief Editor
written by Chief Editor

The Future of Treating Neurodegenerative Diseases: A Leap Forward

Groundbreaking research from the UPV/EHU’s Neurochemistry and Neurodegeneration group has unveiled promising new avenues for treating cognitive impairment in Alzheimer’s and Parkinson’s diseases. The study, led by Dr. Rafael Rodríguez-Puertas and Marta Moreno-Rodríguez, highlights how the cannabinoid and cholinergic systems in the brain could work together to enhance memory and learning in neurodegenerative conditions.

The Role of Neurotransmitter Receptors

This extensive research, spanning over two decades, revealed that certain neurotransmitter receptors, particularly those in the cannabinoid family, play a crucial role in cognitive improvement. “By leveraging the cannabinoid receptors, we’ve found a way to potentially reverse or mitigate memory impairments seen in Alzheimer’s patients,” explained Dr. Rodríguez-Puertas. This discovery not only advances our understanding of neurodegenerative diseases but also opens up new therapeutic strategies.

WIN55.212-2: A Promising Molecule

One of the study’s highlights is the drug WIN55.212-2, which interacts with cannabinoid receptors to restore cognitive functions in rodents. “Rodents treated with this drug performed memory and spatial orientation tasks as effectively as those without brain damage,” noted researcher Marta Moreno. However, the molecule’s broad usage in research poses challenges for commercial exploitation, prompting the team to search for similar molecules.

Developing New Therapeutic Pathways

The team is currently collaborating with CIC bioGUNE and the University of Vigo to synthesize molecules that mimic WIN55.212-2’s effects. These new molecules aim to maintain the therapeutic benefits of the cannabinoid and cholinergic systems while being commercially viable for pharmaceutical companies. If successful, they could fast-track the transition to human clinical trials.

How This Research Affects You

While this research marks a significant milestone, practical applications are still on the horizon. The focus now shifts to toxicity studies and clinical trials to ensure safety and efficacy in humans. This progress could eventually lead to effective treatments for millions of people suffering from neurodegenerative diseases.

Frequently Asked Questions

What is the significance of the cannabinoid system in neurodegeneration?

The cannabinoid system can provide a protective response to early damage in the cholinergic system, which is crucial for memory and learning. Thus, targeting cannabinoid receptors may offer a therapeutic advantage in the early stages of diseases like Alzheimer’s.

Are there ongoing treatments derived from this research?

Currently, the research is in preclinical stages, focusing on finding similar molecules for potential clinical trials. Further development and approval are needed before any treatments become available to the public.

How does this study impact long-term memory health?

By restoring function in the cholinergic and cannabinoid systems, new therapeutic pathways could significantly improve long-term memory and cognitive health, particularly in the early stages of cognitive decline.

Did You Know? The basal forebrain is a key area affected in the early stages of Alzheimer’s, and its recovery plays a pivotal role in memory restoration.

Stay Informed and Engaged

For more insights and updates on neurodegenerative research, follow the University of the Basque Country. To explore related topics, check out our articles on neuroscience innovations. If you found this article useful, consider subscribing to our newsletter for the latest in scientific discoveries and healthcare advancements.

0 comments
0 FacebookTwitterPinterestEmail